drugset / Trial / NCT04092205
Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation
NaSingle-groupOpen-labelTreatment
Summary
A pilot study to explore safety and efficacy of NBMI treatment in patients with Beta Thalassemia Major requiring iron chelation Investigational product: NBMI (N1,N3-bis(2-mercaptoethyl) isophthalamide), INN: Emeramide Indication: Beta Thalassemia Major
Timeline
- Start
- 2019-11-21
- Primary completion
- 2020-07-30
- Completion
- 2020-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Emeramide | Small molecule | 600 mg | — |